Company intelligence / Profile preview
ImmuneAGE Bio
Lausanne, Canton of Vaud, Switzerlandimmuneage.bio ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ImmuneAGE Bio has developed IA101, a non-toxic small molecule that can rejuvenate aged HSCs and aged animal immune function with higher efficacy than any molecule previously published. A less potent natural product analog of IA101 has shown efficacy and safety in multiple human clinical trials, which has de-risked clinical development[7].
- Therapeutic areas
- OncologyHematologyImmunologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on ImmuneAGE Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmuneAGE Bio.